Targeted Therapies for Cancer
ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary Targeted Antibody Payload (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.
Product Pipeline
We have three wholly owned compounds in clinical testing
See our current pipeline...
Our TAP Technology
The first product with our TAP technology, Kadcyla™, is now approved in the United States.
Read press releases about this news:
Our release...
Genentech's release...
FDA's release...